42 completed, 14 recruiting, 9 unknown, 6 withdrawn. 78 Phase 1, 39 Phase 2.
Follow Apnea: new trials by email Literature Review of Apnea trials Research Report on Apnea
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Combination Upper-Airway Electrical and Pharmacological Stimulation for Obstructive Sleep Apnea Combination device and drug: Unilateral hypoglossal nerve stimulation & atomoxetine-plus-oxybutynin (HGNS+AtoOxy), Unilateral hypoglossal nerve stimulation (HGNS), active comparator condition, Atomoxetine-plus-oxybutynin (80/5 mg) (AtoOxy), active comparator condition - Obstructive Sleep Apnea, Sleep-disordered Breathing | Phase 1 / Phase 2 | Recruiting | Brigham and Women's Hospital | 24 | 2026-09-01 | 2026-09-21 |
| The Optimal One-Month Dosing of Lemborexant for Moderate Obstructive Sleep Apnea (OSA) Patients With Low Arousal Threshold Lemborexant 5 MG [Dayvigo] Period 1, Placebo Period 1, Lemborexant 5 MG [Dayvigo] Period 2 - OSA - Obstructive Sleep Apnea | Phase 1 / Phase 2 | Not yet recruiting | Chulalongkorn University | 36 | 2026-09-01 | 2026-07-06 |
| Pharmacokinetics and Placental Transfer of Caffeine Caffeine citrate - Preterm Labor With Preterm Delivery, Premature Birth | Phase 1 | Recruiting | Indiana University | 30 | 2026-06-01 | 2026-06-04 |
| Low-Tech Treatments for Obstructive Sleep Apnea High-Resistance Breathing and Drinking Exercises, Low-Resistance Breathing and Drinking Exercises - Obstructive Sleep Apnea (OSA), Traumatic Brain Injury (TBI) | Phase 1 / Phase 2 | Recruiting | Uniformed Services University of the Health Sciences | 60 | 2026-01-29 | 2026-09-10 |
| DRonabinol Treatment of OSA Dronabinol - Obstructive Sleep Apnea | Phase 1 / Phase 2 | Recruiting | VA Office of Research and Development | 120 | 2025-08-25 | 2026-11-05 |
| Impact of Exogenous Ketones on Sleep Apnea Ketone-IQ, Placebo - Obstructive Sleep Apnea, Sleep | Phase 1 / Phase 2 | Withdrawn | Johns Hopkins University | 2025-01-29 | 2026-09-21 | |
| Impact of Exogenous Ketones on Sleep Disruption in Vulnerable Populations Ketone-IQ (1,3 Butanediol) - Obstructive Sleep Apnea, Sleep | Phase 1 | Suspended | Johns Hopkins University | 30 | 2025-01-29 | 2026-06-23 |
| Apnea of Prematurity Results in Respiratory Distress and Cyanosis. Caffeine Citrate Can Treat It. High-Dose, Low Dose - Apnea of Prematurity | Phase 1 | Active not recruiting | Nishtar Medical University | 114 | 2024-06-03 | 2025-04-01 |
| Exploring the Use of Phototherapy to Improve CPAP Compliance Phototherapy - Obstructive Sleep Apnea | Phase 1 | Recruiting | University of Alberta | 30 | 2024-01-05 | 2026-05-08 |
| Trazodone on OSA Endotypes Placebo oral tablet, Trazodone Hydrochloride - Obstructive Sleep Apnea | Phase 1 / Phase 2 | Recruiting | Brigham and Women's Hospital | 18 | 2024-01-01 | 2025-02-06 |
| Bioavailability, Bioequivalence and Tolerability of IHL-42X Compared to the Reference Drugs IHL42X, Acetazolamide 250 MG, Dronabinol 2.5 MG - Obstructive Sleep Apnea | Phase 1 | Completed | Incannex Healthcare Ltd | 125 | 2023-09-08 | 2025-01-17 |
| Rescue Pharmacotherapy for OSA Placebo, Acetazolamide, Trazodone - Obstructive Sleep Apnea | Phase 1 / Phase 2 | Recruiting | Brigham and Women's Hospital | 70 | 2023-07-01 | 2026-07-15 |
| Effects of Lemborexant as a Treatment for Moderate-to-severe OSA Patients With Low Arousal Threshold Lemborexant 5 MG Oral Tablet [Dayvigo] Day 1, Lemborexant 5 MG Oral Tablet [Dayvigo] Day 2, Placebo Day 1 - OSA | Phase 1 / Phase 2 | Completed | Chulalongkorn University | 10 | 2023-02-01 | 2025-09-17 |
| Acetazolamide on REM OSA Placebo oral capsule, Acetazolamide - Obstructive Sleep Apnea | Phase 1 / Phase 2 | Completed | Brigham and Women's Hospital | 11 | 2023-01-30 | 2026-01-20 |
| Cerebral Blood Flow and Ventilatory Responses During Sleep in Normoxia and Intermittent Hypoxia Drug Lowering Cerebral Blood Flow (CBF) and Normoxia Sleep, Drug Lowering CBF and Intermittent Hypoxia Sleep, Placebo and Normoxia Sleep - Obstructive Sleep Apnea of Adult, Hypoxia, Brain | Phase 1 / Phase 2 | Recruiting | University of Calgary | 12 | 2023-01-01 | 2026-05-01 |
| Intermittent Hypoxia-initiated Plasticity in Humans: A Multi-pronged Therapeutic Approach to Treat Sleep Apnea and Overlapping Co-morbidities Mild Intermittent Hypoxia, Sham MIH - Obstructive Sleep Apnea | Phase 1 / Phase 2 | Recruiting | VA Office of Research and Development | 60 | 2023-01-01 | 2025-12-04 |
| BAY2586116 Nasal Spray and OSA Severity BAY2586116, Placebo - Sleep Apnea, Obstructive | Phase 1 | Completed | Flinders University | 10 | 2022-08-31 | 2023-02-15 |
| Use of Passive Myofunctional Appliances for Snoring and Mild Obstructive Sleep Apnea passive myofunctional appliance, standard oral appliance - Sleep Apnea, Obstructive | Phase 1 | Recruiting | University of Alberta | 40 | 2022-07-23 | 2026-09-16 |
| Atomoxetine and DAW2022 on OSA Severity Placebo oral capsule, Atomoxetine Oral Capsule [Strattera] - Obstructive Sleep Apnea | Phase 1 / Phase 2 | Recruiting | Brigham and Women's Hospital | 18 | 2022-06-01 | 2026-07-10 |
| Identifying Sleep Apnea Patients That Best Respond to Atomoxetine Plus Oxybutynin Therapy Atomoxetine, Oxybutynin - Obstructive Sleep Apnea | Phase 1 / Phase 2 | Unknown | Brigham and Women's Hospital | 22 | 2022-05-05 | 2023-10-18 |
Showing 20 of 78. Sign in to see all of them.
Sleep Apnea, Obstructive (57) · Sleep Apnea Syndromes (27) · Premature Birth (3) · Pulmonary Disease, Chronic Obstructive (3) · Snoring (3) · Stroke (3) · Bronchopulmonary Dysplasia (2) · Ketosis (2) · Obesity (2) · Sleep Wake Disorders (2) · Airway Obstruction (1) · Alzheimer Disease (1) · Behavior (1) · Brain Injuries, Traumatic (1)
Respiratory Tract Diseases (78) · Respiration Disorders (77) · Dyssomnias (73) · Nervous System Diseases (73) · Sleep Disorders, Intrinsic (73) · Sleep Wake Disorders (71) · Sleep Apnea Syndromes (46) · Pathological Conditions, Signs and Symptoms (21) · Signs and Symptoms (18) · Signs and Symptoms, Respiratory (15) · Lung Diseases (6) · Brain Diseases (5) · Central Nervous System Diseases (5) · Nutritional and Metabolic Diseases (5)
Atomoxetine Hydrochloride (5) · Acetazolamide (4) · lemborexant (4) · Oxygen (3) · Trazodone (3) · caffeine citrate (3) · Dronabinol (2) · TAK-925 (2) · Tablets (2) · oxybutynin (2) · 1,3-butylene glycol (1) · Atorvastatin (1) · Celecoxib (1) · Cerebrovascular Circulation (1) · Contraceptives, Oral (1)
Brigham and Women's Hospital (14) · VA Office of Research and Development (4) · Johns Hopkins University (3) · Merck Sharp & Dohme LLC (3) · Chulalongkorn University (2) · Eisai Inc. (2) · Mayo Clinic (2) · University of Alberta (2) · University of Calgary (2) · 5i Sciences, Inc. (1) · Academic Centre for Dentistry in Amsterdam (1) · Ain Shams University (1) · Apnimed (1) · Axsome Therapeutics, Inc. (1) · Bayer (1)
United States (51) · Canada (6) · Australia (4) · Belgium (2) · Thailand (2) · China (1) · Egypt (1) · Germany (1) · Israel (1) · Italy (1) · Japan (1) · Netherlands (1) · Pakistan (1) · Poland (1) · Portugal (1)
Scott A Sands, PhD (3) · Jonathan Jun, MD (2) · Sarocha Vivatvakin, MD (2) · Amy M Sawyer, PhD (1) · Anna Thomas, MD (1) · Anthony Doufas (1) · Atul Malhotra, MD (1) · Bharati Prasad, MD (1) · Bradley A Edwards, PhD (1) · Carl J Stepnowsky, PhD (1) · Charles Bowden, MD (1) · Charles V Smith, PhD (1) · Ching-Lung Liu, MD (1)
PMID 40848323, PMID 21632834, PMID 21856678, PMID 22131599, PMID 22302299, PMID 22572632, PMID 22893765, PMID 24122944, PMID 24815497, PMID 25805361, PMID 26194728, PMID 27092703, PMID 27110692, PMID 29246264, PMID 30395486, PMID 33305817, PMID 33491327, PMID 35306405, PMID 35947827, PMID 36805833, PMID 37677076, PMID 38286618, PMID 38346816, PMID 39069967, PMID 39266012, PMID 39502777, PMID 39688178, PMID 40088388, PMID 40135690, PMID 40158847, PMID 41025403, PMID 41072928, PMID 41781273, PMID 42730864
2018 (2), I01CX002632 (1), P30DK072476 (1), R00NR011173 (1), R01HL065176 (1), UL1RR026314 (1)